Oncology Times Publishes NETs Data
May 16th, 2018
The prevalence of neuroendocrine tumors (NETs) in the US is approximately 112,000 and between and 8,000-12,000 patients are newly diagnosed each year. Many know that NETs is a slow-growing disease and patients can live for years with the disease. Its number one – and most debilitating symptom – is chronic diarrhea.
Our team is dedicated to providing NETs patients with an alternative, natural and effective solution, called enterade®, to help reduce diarrhea and strengthen the digestive tract. As we continue to gather clinical data, we’re pleased to share results from a subset of s patients were recently published in an article in Oncology Times entitled: “Anti-Diarrheal Efficacy of Oral Rehydration Solution in GEP-NET Patients.”
In this subset, a total of eight patients received enterade – a natural, sugar-free amino acid beverage. Five of eight (62%) patients reported improvement in diarrhea within 6 days of receiving enterade. The responders also had 50% reduction in their stool output. Mean stools dropped from six per day to three per day in the responder population.
Updated results and recent publication in Oncology Times continue to show that enterade is a clinically proven and effective solution for NETs patients. In collaboration with the University of Kentucky Markey Cancer Center (MCC), the team will continue to share results and highlights from our ongoing studies.
For more information about how enterade works, check out this short video. enterade is also available on www.enterade.com or Amazon.com in two different flavors – no prescription required but always use under the supervision of your healthcare provider.